Kymera Therapeutics Inc (KYMR)

05:00 AM

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga

05:00 AM

11:08 AM

Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from Guggenheim | KYMR Stock News - GuruFocus

11:08 AM

10:56 AM

Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus

10:56 AM

10:14 AM

Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus

10:14 AM

09:02 AM

Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK

09:02 AM

09:00 AM

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech

09:00 AM

08:37 AM

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com

08:37 AM

07:29 AM

BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

07:29 AM

01:39 AM

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks

01:39 AM

May 10, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025

May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

May 10, 2025

May 10, 2025

Kymera advances oral drug for autoimmune diseases - Investing.com

May 10, 2025

May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus

May 10, 2025

May 10, 2025

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World

May 10, 2025

May 10, 2025

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

May 10, 2025

May 10, 2025

Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India

May 10, 2025

May 10, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com

May 10, 2025

May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks

May 09, 2025

May 09, 2025

Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks

May 09, 2025

May 09, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa

May 09, 2025

May 09, 2025

Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada

May 09, 2025

May 09, 2025

Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 09, 2025

May 09, 2025

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research

May 09, 2025

May 09, 2025

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 09, 2025

May 09, 2025

Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com

May 09, 2025

May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Strong Q1 Performance | KYMR Stock News - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics Introduces KT-579 Targeting IRF5 - TipRanks

May 09, 2025

May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update | KYMR Stock News - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update - The Manila Times

May 09, 2025

May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases - The Manila Times

May 09, 2025

May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases | KYMR Stock News - GuruFocus

May 09, 2025

May 09, 2025

Kymera Therapeutics Advances Oral Immunology Pipeline with Promising New Program Targeting IRF5 for Autoimmune Diseases - Nasdaq

May 09, 2025

May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire Inc.

May 09, 2025

May 08, 2025

What's Next: Kymera Therapeutics's Earnings Preview - Nasdaq

May 08, 2025

May 08, 2025

What To Expect From Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings - GuruFocus

May 08, 2025

May 08, 2025

Dimensional Fund Advisors LP Sells 38,871 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 08, 2025

May 07, 2025

KYMERA THERAPEUTICS Earnings Preview: Recent $KYMR Insider Trading, Hedge Fund Activity, and More - Nasdaq

May 07, 2025

May 07, 2025

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference - The Manila Times

May 07, 2025

May 07, 2025

Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Friday - Defense World

May 07, 2025

May 06, 2025

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $56.36 - Defense World

May 06, 2025

May 02, 2025

Kymera Therapeutics Inc’s results are impressive - uspostnews.com

May 02, 2025

May 02, 2025

Market Momentum Report: Kymera Therapeutics Inc (KYMR)’s Positive Close at 34.55 - DWinneX

May 02, 2025

May 01, 2025

Invesco Ltd. Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 01, 2025

May 01, 2025

Wells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 01, 2025

Apr 28, 2025

Closing Figures Unveiled: Kymera Therapeutics Inc (KYMR) Drop -7.60, Closes at 27.37 - DWinneX

Apr 28, 2025

Apr 26, 2025

JPMorgan Chase & Co. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Apr 26, 2025

Apr 25, 2025

Why Kymera Therapeutics (KYMR) Stock is Moving Today - GuruFocus

Apr 25, 2025

Apr 25, 2025

Why Kymera Therapeutics Stock Crushed it This Week - MSN

Apr 25, 2025

Apr 25, 2025

Kymera Therapeutics Inc (KYMR) Performance and Fundamentals Dashboard tells a completely different story - Sete News

Apr 25, 2025

Apr 25, 2025

Kymera Therapeutics Inc [KYMR] Shares Rise 9.32 % on Thursday - knoxdaily.com

Apr 25, 2025

Apr 25, 2025

KYMR’s Stock Market Adventure: -16.58% YTD Growth Amidst Volatility - investchronicle.com

Apr 25, 2025

Apr 25, 2025

Daily Market Movement: Kymera Therapeutics Inc (KYMR) Sees a 9.32 Increase, Closing at 33.56 - DWinneX

Apr 25, 2025

Apr 24, 2025

Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 F - GuruFocus

Apr 24, 2025

Apr 24, 2025

Kymera Therapeutics (KYMR) to Reveal New Candidate and Q1 2025 Financials | KYMR Stock News - GuruFocus

Apr 24, 2025

Apr 24, 2025

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025 - The Manila Times

Apr 24, 2025

Apr 24, 2025

Kymera Unveils Revolutionary Oral Drug Program Targeting Untapped Autoimmune Disease Pathway - Stock Titan

Apr 24, 2025